Cas:62176-35-6 5-bromo-2-[(3-chlorophenyl)methoxy]benzoic acid manufacturer & supplier

Chemical Name:5-bromo-2-[(3-chlorophenyl)methoxy]benzoic acid

CAS.NO:62176-35-6

Synonyms:5-bromo-2-{[(3-chlorophenyl)methyl]oxy}benzoic acid;5-bromo-2-[(3-chlorobenzyl)oxy]benzoic acid

Molecular Formula:C₁₄H₁₀BrClO₃

Molecular Weight:341.58400

HS Code:2918990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:467.7ºC at 760 mmHg

Density:1.59g/cm3

Index of Refraction:1.635

PSA:46.53000

Exact Mass:339.95000

LogP:4.37970

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-bromo-2-{[(3-chlorophenyl)methyl]oxy}benzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-bromo-2-[(3-chlorobenzyl)oxy]benzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-bromo-2-{[(3-chlorophenyl)methyl]oxy}benzoic acid Use and application,5-bromo-2-[(3-chlorobenzyl)oxy]benzoic acid technical grade,usp/ep/jp grade.

Related News: In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. 5-bromo-2-[(3-chlorophenyl)methoxy]benzoic acid manufacturer Darzalex does have another regimen approved for the same myeloma population. Darzalex combined with Takeda’s Velcade, melphalan and prednisone (VMP) reduced the risk of death by 40% in the phase 3 ALCYONE trial. But disease progression had already occurred in half of patients on the Darzalex-VMP combo after about three years of follow-up, a much shorter period than the five-year mark the Darzalex-Rd regimen is approaching. 5-bromo-2-[(3-chlorophenyl)methoxy]benzoic acid supplier The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy. 5-bromo-2-[(3-chlorophenyl)methoxy]benzoic acid vendor In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. 5-bromo-2-[(3-chlorophenyl)methoxy]benzoic acid factory FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus.